This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk00: Please stand by. Your program is about to begin. If you need assistance during the conference today, please press star zero. Good morning, everyone. My name is Katie, and I will be your conference operator. At this time, I would like to welcome everyone to the Eagle Pharmaceuticals second quarter 2022 financial results. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer period. At that time, if you have a question, please press star and 1 on your telephone keypad. As a reminder, this conference call is being recorded today, August 9, 2022. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.
spk02: Thank you, Operator. Welcome to Eagle Pharmaceuticals' second quarter 2022 earnings call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle's President and Chief Executive Officer, Scott Tariff, Chief Financial Officer, Brian Cahill, and Vice President of Medical Affairs, Dr. Mike Greenberg. This morning, Eagle issued a press release detailing its financial results for the three months ended June 30, 2022. This press release and a webcast of this call can be accessed through the investor section of the Eagle website at eagleus.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Eagle Pharmaceuticals management as of today and involve risks and uncertainties, including those noted in this morning's press release and are filing through the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. Eagle Pharmaceuticals specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. A telephone replay will be available shortly after completion of this call. You'll find the dial-in information in today's press release. The archived webcast will be available for one year on our website at eagleus.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on August 9, 2022. Since then, Eagle may have made announcements related to the topics discussed, so please refer to the company's most recent press releases and SEC filings. And with that, I'll turn the call over to Eagle's President and CEO, Scott Tariff.
spk04: Thank you, Lisa. Good morning, everyone, and thank you for joining our call today. We're pleased that our second quarter 2022 results are bearing out the vision that we have been articulating for Eagle for some time now. Over the last year or so, we have focused on strategically building out our portfolio through acquisition, licensing agreements, and launches of organically developed products with a stated expectation that we would double our revenue and more than double our earnings in 2022. We are achieving that aspiration. In fact, our first half 22 non-GAAP earnings came in at $5.60 per share, already more than double the full year 2021 number. And our first half 22 revenues of $190 million already exceeded our revenues for all of 2021. In just six months, we have already outperformed our best year. Our main objective is to grow from here. The largest disconnect we need to bridge for our investors is that our internal forecast suggests that we will continue at the 2022 level in 23, with significant growth thereafter. This is also without further deploying our cash and balance sheet. Let me take the next few moments to explain our point of view. First half 2022 sales of Deja Press and Pemfexi combined reached nearly $100 million. Our expectations for the third and fourth quarters of this year are that we will remain quite profitable. Our cash position is strong at $37 million with $86 million in receivables for total cash plus receivables of $122 million as of June 30 of 22. And this is after acquisition of Acacia, and we have only $48 million in outstanding debt we are confident that 22 rebased our revenue and earnings. 2022 continues to be an active and exciting period for EGLE as we broaden our ability to bring much needed medicines to those who depend on them. It comes down to the fact that 2022 is a year of significant step up in revenue and earnings for us. The questions we are asked most frequently are, where does EGLE go from here? Can Eagle continue to grow from here after posting such significant EPS growth? And what do 23 and 24 look like? I would like to make it very clear that our objective is to use 2022 as a springboard for further growth. We have a very good chance of achieving growth next year and beyond. On the upside, we have added Bar-Emsys and Byfava and hopefully Landilol to our product mix next year. We also expect to grow Pempexi year over year. On the downside, vasopressin will decline, and we'll lose some Vendeca loyalty in 23. All in all, with our current product lineup, our projections today lead us to expect a very strong 2023. As previously mentioned, we have $122 million in cash and receivables, and we do not require a major deployment of cash to achieve our goals. Add into the mix the potential of Fulvestran, Cal O2, and now the three NLR pipeline opportunities announced this morning, and we see the potential for dramatic growth from where we are today. To be clear, we do not need a significant acquisition to achieve growth in 2023. Let's see how it all unfolds, but we are very focused on growth beyond the significant earnings and revenue step-up that we have achieved so far in 22. Let's discuss Pemfexi and the rest of the opportunities in further detail. Pemfexi is a unique market and one that is new to us. We developed a product with many benefits. Our customers have embraced Pemfexi as evidence from our first half sales of $54 million. As this market matures, we believe many of our customers are highly likely to use a generic form of Olympta through the end of this year. This is due to the way that generics are reimbursed in the first six months of their life cycle. Thereafter, we expect the dynamics in the market will allow many of these customers to transition their demand back to Pemfexi, starting in the first quarter of 23. As of today, we believe that we will sell more Pemfexi in 2023 than we have in 2022. Turning now to our hospital business, and our recent acquisition of Acacia, which directly supports our stated objective of becoming a leading diversified pharmaceutical company. With the closing of the transaction, Eagle picked up our Emsys and Byfava, two commercially compelling FDA-approved hospital products with meaningful differentiation. Both are new chemical entities with patent life extending into the early 2030s, and we are seeing a lot of excitement around these two products. Let me spend a few minutes walking through why we think there is such a strong synergistic fit here and a sizable opportunity. Baramsis is the first and only antiemetic approved by the FDA for rescue treatment of postoperative nausea and vomiting, referred to as POMD, despite prophylaxis. We already call on most of these same healthcare providers and institutions. Paramsys is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV. The total estimated annual U.S. addressable market for prophylaxis and rescue is $2.7 billion. The second product by Fabo is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Here, the estimated addressable market in the procedural sedation is more than $400 million per year in the United States. As we commenced the integration, we were impressed with Acacia's previous plans and the positioning of our M system by FAVA. In our view, the two products were underinvested both from a cost and manpower perspective. Additionally, the products were launched into a very difficult COVID environment in which access to decision makers and prescribers was limited. Acacia had approximately 70 employees prior to the acquisition, of whom we retained approximately 20. Most of these individuals are now members of our commercial team. In reviewing the future plans, we were immensely impressed with the vision, experience, and leadership skills of Acacia's Deborah Hussain, who we recently welcomed as EGLE Senior Vice President, Head of Commercials. Eagle's team is now at its peak commercial strength with approximately 50 individuals. Deborah brings nearly 25 years of pharmaceutical industry experience leading commercial launches in the hospital and critical care space, having spent 22 years at Eli Lilly prior to Acacia. We look forward to her leadership as we work to realize the full potential of our emphasis and by favor and future launch products. Francis and Byfavo serve to diversify and complement our revenue streams and have the potential to accelerate our growth trajectory and strengthen our advantage in acute care. We believe that peak U.S. annual sales of the two products combined could potentially total $275 million, and we look forward to demonstrating the strength of the acquisition as usage builds over the next 12 months. Now turning to Landialol. On June 1st, we announced the submission of a new drug application to the FDA, seeking approval for Landialol, an ultra-short-acting, cardio-selective beta blocker. Landialol is a leading hospital critical care product in Europe and Japan. Based on feedback from FDA, we expect approval around mid-next year, with a commercial launch soon thereafter. Together with Baramsys and Bifava, this would give us three newly approved NCEs with strong patent life going into their growth stage, with projections of peak sales just shy of $400 million. Our hospital pipeline is very strong. We believe Cal O2 has blockbuster potential and could be a groundbreaking opportunity in severe bacterial pneumonia, which is a leading cause of death worldwide. In simple terms, CalO2 is being developed as an add-on to the clinically indicated antibiotic treatment that neutralizes bacterial toxins from the body. It is well established medical understanding that these toxins significantly contribute to the severity of pneumonia. We start our clinical trials later this year and anticipate interim results at the end of 23. Importantly, the trial asked clinicians to add Calo2 to their current pneumonia treatment regimen. In the fall, we will begin opening what we expect will eventually be over 100 clinical sites worldwide. Now we add Analar to the mix, strengthening our hospital pipeline. This transaction broadens our acute care business with the addition of a portfolio of novel NCEs with strong intellectual property protection from the mid-2030s into the early 2040s, including composition of matter patterns. DNA001 is a new chemical entity with a mechanism of action that's simply described as a molecule that stimulates breathing. Think of it like a pharmacologic ventilator. You can imagine a number of indications where being able to stimulate breathing would be extremely valuable. At present, Anilara has elected to move forward with three targeted indications. Postoperative respiratory depression, its most advanced development program. Community drug overdose, a problem that continues to increase in prevalence and severity. And apnea of prematurity, a common condition in preterm infants. We see tremendous potential to address significant unmet medical needs for millions of patients worldwide suffering from acute respiratory depression. This is another example of our acquiring pipeline products that represent a strong strategic fit with our specialized sales and marketing organization. And we believe will serve to expand our portfolio of hospital and anesthesia products. We believe we will have approval for these postoperative respiratory depression in 2026 and community drug overdose thereafter. Now let me turn it over to Dr. Mike Greenberg, our Vice President of Medical Affairs, who will explain in greater detail about the initial targeted indications for ENA001. Mike?
spk03: Thank you, Scott. ENA001 is a promising molecule and one that we believe has several important uses. It's an NCE with a unique mechanism of action being developed as an agnostic respiratory stimulant. Agnostic in this case means that it stimulates breathing irrespective of the cause of respiratory depression because it utilizes the body's innate respiratory control system. Current treatments may have limited use. For example, naloxone only reverses respiratory depression due to opioids, and flumazenil only reverses benzodiazepines. Because ENA001 is agnostic, It reverses respiratory depression due to opioids, benzodiazepines, even propofol, and we see potential use across multiple patient populations. The first indication is postoperative respiratory depression, which is common in patients recovering from surgery and anesthesia. In fact, up to 36% of patients are at high risk of postoperative respiratory depression, which is associated with an increased risk of in-hospital mortality, increased length of stay, and higher costs. ENA001 has the potential to treat respiratory depression without interfering with pain suppression or sedation. This and the potential ability of ENA001 to address respiratory depression associated with multiple agents, such as opioids, benzodiazepines, or propofol, differentiates it from other available options. The second targeted indication is community drug overdose. Sadly, drug overdose deaths are at a record high, and polysubstance abuse is increasingly common. Current pharmacologic options are limited in that they only address a single substance of abuse, typically opioids, and are usually implicated in inducing a withdrawal syndrome. ENA-001 has the potential to treat respiratory depression associated with polysubstance abuse without inciting the withdrawal effect experienced with opioid antagonists, which can be a potential safety consideration. And the IM, or intramuscular formulation, being developed in conjunction with the Biomedical Advanced Research and Development Authority, or BARDA, has the potential to make this a treatment available in the hospital and in the community setting. The third indication is acne of prematurity, referred to as AOP. The prevalence of AOP increases with decreasing neonatal gestational age and birth weight, and is present in up to 80% of infants born at less than 27 weeks of gestation. Pharmacologic treatment for these neonates is typically limited to caffeine or other methylxanthines. This proposed treatment could be used as monotherapy or in conjunction with a standard of care. We look forward to providing updates as we advance the pipeline. I'll now turn the call back to Scott.
spk04: Thank you, Mike, for highlighting the important differentiators. Continuing with our pipeline. Let me say a few words about fulvestrin. We spent about $6 million on an additional study this quarter representing roughly 75% of our external R&D spend here in Q2. We expect to have a preliminary data readout in about a month or so. If the readout is positive, we hope that we will have finally figured out this very complex product, which we believe could have tremendous benefit to breast cancer patients. Positive findings would afford us an important opportunity to provide meaningful value to our shareholders as well. If the study results are not positive, we will permanently discontinue this undertaking, and no more money will be invested other than unwinding it. With that, I'd like to turn the call over to Brian Cahill to discuss our second quarter financials. Brian?
spk05: Thank you, Scott, and good morning. In the second quarter of 2022, total revenue was $74.1 million compared to $48.1 million in 2Q of 2021, primarily reflecting continued revenue from sales of Vasopressin and Pemfexi. Product sales during the second quarter were $49.2 million compared to $19.6 million in 2Q of 2021. Basopressin sales were $11.3 million, and Penfexi sales were $16.5 million in the second quarter of 2022. Belrapsa product sales were $8.1 million in the second quarter of 2022, compared to $7.6 million in Q2 of 2021. Second quarter Rianodex product sales were $8.8 million, compared to $7.9 million in 2Q of 2021. 2Q 2022 royalty revenue was $24.9 million compared to $28.5 million in the prior year quarter. Royalty revenues include royalties earned on sales of Bendecca in the U.S. and Triakasem in Japan. On the expense front, R&D expenses were $11.4 million for the second quarter of 2022 compared to $9.9 million in the prior year quarter. This increase is largely attributable to clinical expense for Fulvestrant and spend on Cal O2. Excluding stock-based compensation and other non-cash and non-recurring items, second quarter 2022 non-GAAP R&D expense was $10.8 million. We continue to expect R&D spend in 2022 on a non-GAAP basis to be between $46 and $50 million. This reflects expected clinical and CMC work on Cal O2 and Fulvestrant and costs of other ongoing programs, including the post-approval obligations for the newly acquired Acacia products. SG&A expenses in the second quarter of 2022 were $36.8 million compared to $16.6 million in the second quarter of 2021. This increase was primarily related to costs associated with the acquisition of Acacia, including severance expense as well as other deal costs. Additionally, external sales and marketing expense increased through the launch of Pemfexi. Excluding stock-based compensation and other non-cash and non-recurring items, the second quarter 2022 non-GAAP SG&A expense was $15.2 million. We expect our SG&A spend in 2022 on a non-GAAP basis to be between $62 and $66 million. This increase from prior guidance is inclusive of the headcount and external costs associated with commercializing Barhemsus and Bifavo. Net loss for the second quarter of 2022 was $9.5 million, or 74 cents per basic and diluted shares. compared to net income of $3.6 million, or $0.28 per basic and $0.27 per diluted share in the prior year period. Adjusted non-GAAP net income for the second quarter of 2022 was $20.3 million, or $1.58 per basic and $1.56 per diluted share, compared to adjusted non-GAAP net income of $12.4 million, or $0.95 per basic and $0.93 per diluted share in the prior year period. For a full reconciliation of non-GAAP measures to the most comparable GAAP measures, please see the tables at the end of our earnings press release. As of June 30, 2022, and following the completed acquisition and synergizing of Acacia, the company had $36.6 million in cash and cash equivalents We had $85.9 million in net accounts receivable and $47.9 million in outstanding debt, resulting in $74.6 million in net cash plus receivables. With that, I'll ask the operator to open the call for questions. Operator, please go ahead.
spk00: Thank you. At this time, if you would like to ask a question, please press star 1 on your touchtone phone You may remove yourself from the queue at any time by pressing star two. Once again, that is star one. If you would like to ask a question, we will pause for a moment to allow questions to queue. Thank you. Our first question will come from Tim Lugo with William Blair. Your line is now open.
spk06: Hey, guys. This is Lockwood. I'm Tim. Thanks for taking the question, and congrats on another strong quarter and another deal in the works. So, Scott, I was wondering, you mentioned the sort of the payer dynamics around generic Olympia and how that will impact their first two quarters of launch. I was wondering if you can give any color on sort of what you've seen so far since they launched. I know it's not been very long, but have you seen sort of slowing growth or declining growth? use of Pemfecti, any sort of commentary you could give there would be great. And second, on the launch of Favo and Barhamsus, can you just talk about what the uptake expectations should be there? Because I know they came with some reimbursement already sort of underway. So How should we think about the uptake of them?
spk04: Awesome. Well, thank you, and good morning. It's nice to hear from you today. So taking Pemfexi first, you know, it's just an unusual market that we haven't been in previously. Generics come into the market, and their price is, you know, below where the market was, obviously. And the way reimbursement works, they'll wind up, you know, there'll be heavy generic usage in the next two quarters, three and four. And then based on the attributes of Pemfexi, we expect those sales to come back to us pretty significantly. As we mentioned, you know, a little while ago, we expect Pemfexi sales to grow in 2023. over 22, and you know, we did over $50 million in the first half this year, so we're pretty excited about Pemfexi. It really turned out to be a great product for us. And then, as far as our Emsys and Bifavo go, you know, Acacia actually did a very good job. They have a very significant number of formulary victories. And now it's really all about pull through. We have the most significant number of commercial members in the team on it now. It's obviously a focus of ours. We don't know exactly how the ramp is going to work out. We're going to have to see. But as we mentioned, the expectation is those two products will reach $275 million in at peak sales, which is tremendous for our size, tremendous for the company. Let's see what the next two, three quarters look like as we put the new team in place and try to pull through. But, you know, we're just very excited about it. And if we're right, if we're anywhere close to right, you can see where the trajectory of this company winds up. You know, put Landy Law in there next year as well, same sales force. And, you know, that's our excitement right now. Thanks.
spk00: Thank you. Our next question will come from David Anselm with Piper Sandler. Your line is now open.
spk01: Thanks. So just a couple. So first, I know you've talked about this in the past, but I thought it would make sense to just get a refresher on your latest thinking on where Your Ben Demustine, I should say, Bendecca share will go amid the presence of generics on the legacy form. So just talk about how you're thinking about market dynamics next year for that franchise. And then secondly, with VASO and competitive dynamics evolving, I think you've said in the past that you expect it even with more competition, to be a meaningful contributor. Can you just talk to how you're thinking about that? If you can't quantify it, at least, you know, provide some qualitative color on what you mean by meaningful, even amid evolving competitive dynamics going forward. Thanks.
spk04: Thank you, David. So, you know, let me try to summarize your two questions. On Bendamustine, you know, as we continue to look at the landscape and our thinking is solidified by what we see with Pemfexi, a couple of items to bring up. First of all, Bendec is by far the best product on the market. It's a 10-minute infusion instead of 30 and 60 minutes, and it has been embraced, you know, very successfully with everyone involved, patients and caregivers, nurses, and physicians. When we receive competition from TRAN later in the year, early next year, those are therapeutic substitutions to Bendecca. They're not generic substitutions for Bendecca. Bendecca will be protected into 2028. So Bendecca will clearly be a meaningful product to the company for many years to come. It's just going to be difficult for that switch to take place to a therapeutic alternative with the benefits of Bendecca. We've been pretty consistent. You know, we think the loss will be, you know, give or take 30% of our revenue, which is very manageable for the company. And with the growth that we have, we don't believe that the, you know, the decline that we'll get from Bendecca is going to be significant relative to the size of the company. And our view of that is more solidified now than it has been. On terms of Azo, You know, what we've always said in the past, David, is that we looked at basal and panfexy combined. You know, in the case of vasopressin, as more people come into the market, obviously the vasopressin market is going to decline for us. I mean, there's no way of getting around that. We'll just have to see over time here how many people actually come into the market and what happens to price. It's hard to predict. So on the other side, we have Pemfexi, which is very strong and is expected to grow next year compared to this year. And it's a big number, right? We've already done over $50 million of Pemfexi this year. And so we expect a decline in Bezo, an increase in Pemfexi, and all in all growth in those two products for a while. You know, we'll have to see how long that is, but You know, we expect growth from these two products or at least significant earnings from the two products in the near and midterm, and we'll just have to see how it unfolds. But when you take in the ups and the downs, our expectation is 23 is going to be pretty close to 22, and that's without deployment of our balance sheet or cash. So we're pretty excited about the future. Okay. Thank you. Thanks, David.
spk00: Thank you. It appears we have no further questions at this time. I'll now turn the program back over to Scott Tara for any additional or closing remarks.
spk04: Well, thank you again, everyone, for joining our call. We've been making significant progress in diversifying our revenue base and increasing the breadth of our product and development portfolio. And it's only mid-year, and we've already turned into best earnings performance in the history of our company. And we look to sustain and accelerate the growth, and we continue to support our commercial launches and broaden our portfolio through acquisitions, such as Acacia and now our investment in potential to acquire Analar, both of which would enhance our position in hospital critical care. And we appreciate your interest and support of EGLE and look forward to sharing more updates as we move forward. Thank you again, and stay well. I appreciate it.
spk00: Thank you, ladies and gentlemen. This concludes today's event. You may now disconnect.
Disclaimer